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Brief Definit ive Report
B cell development is a tightly controlled pro­
cess that promotes the survival and expansion 
of B cells with affinity for invading organisms 
while eliminating autoreactive B cells and thereby 
preventing autoimmunity (Browning, 2006; 
Allman and Pillai, 2008). The recent clinical 
success of B cell targeted therapies in a multi­
tude of autoimmune disorders has highlighted 
the potential role of B cells in disease pathology. 
Work in the last several decades has also revealed 
that B cells have alternative effector functions 
in addition to antibody production, and can 
play a role in the pathology of a multitude of 
human diseases and provide additional thera­
peutic intervention points (Browning, 2006; 
Gürcan et al., 2009).
Although much has been discovered about 
lymphocyte development and activation through 
the use of traditional gene targeting approaches, 
it also has its limitations. These include require­
ments for a gene in embryonic development, the 
development of a particular cell type, or a hy­
pothesis that a gene is involved in the function of 
a particular cell type or pathway. Forward ge­
netic approaches have classically proven to be 
valuable tools in many model organisms, and 
work from the last 10 years has shown that it 
can also be a useful tool in mice (Beutler et al., 
2006; Cook et al., 2006). Random mutagenesis 
also provides the opportunity to identify mutants 
with reduced or increased activity as opposed 
to full ablation, which can provide insight into 
how a particular molecule is functioning.
To this end, we used a forward genetic 
screen using N­ethyl­N­nitrosourea (ENU)–
induced mutagenesis in mice to identify novel 
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B cell development requires tight regulation to allow for the generation of a diverse reper-
toire while preventing the development of autoreactive cells. We report, using N-ethyl- 
N-nitrosourea (ENU)–induced mutagenesis, the identification of a mutant mouse (chompB) 
with a block in early B cell development. The blockade occurs after the transitional 1 (T1) 
stage and leads to a decrease in mature B cell subsets and deficits in T cell–dependent 
antibody responses. Additionally, chompB mice have decreases in myeloid dendritic cells 
(DCs). The mutation was mapped to the intramembrane protease signal peptide peptidase-
like 2a (Sppl2a), a gene not previously implicated in immune cell development. Proteomic 
analysis identified the invariant chain (CD74) as a key substrate of Sppl2a and suggests 
that regulated intramembrane proteolysis of CD74 by Sppl2a contributes to B cell and DC 
survival. Moreover, these data suggest that modulation of Sppl2a may be a useful thera-
peutic strategy for treatment of B cell dependent autoimmune disorders.
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B cells in chompB mutants (Fig. 1 D). A similar reduction in 
mature B cells was also observed in peripheral lymph nodes 
of chompB mice (Fig. 1 E); however, B1 cells in the peritoneal 
cavity were unchanged (Fig. 1 F). Analysis of DCs in the 
spleen revealed a significant decrease in myeloid DCs (mDCs) 
in chompB mice, whereas plasmacytoid DCs (pDCs) were less 
affected (Fig. 1 G). Other immune cell subsets were un­
affected in chompB mutants, including T cells, NK cells, and 
myeloid cells (unpublished results). Despite the relatively 
ubiquitous expression of Sppl2a (Fig. S1 B), the phenotype 
of chompB mice appears to be lymphoid restricted as gross 
analysis did not reveal any other obvious abnormalities (unpub­
lished data; Lattin et al., 2008).
To determine the cellular origin of the chompB mutant 
phenotype, mixed BM chimeras were generated. Analysis 
of recipient mice revealed similar reductions in T2, MZ, and 
FO B cells and mDCs from chompB mutant BM, consistent 
with data from intact animals (Fig. 1, H and I). Analyses of 
single BM chimeras confirmed these observations (unpub­
lished results).
Sppl2a is required for immunoglobulin production  
and T cell–dependent antibody responses
We next assessed B cell function by measuring serum immuno­
globulin levels and the antigen­specific response after immu­
nization. Significant decreases in IgG1, IgG2b, and IgG3 levels 
were observed in chompB mice compared with controls, 
whereas levels of IgA and IgM were less affected (Fig. 2 A). 
Consistent with the initial screening results, chompB mutant 
mouse strain (chompB) with a heritable recessive mutation 
that leads to decreased B cells and T cell–dependent anti­
body responses and mapped it to the gene encoding signal 
peptide peptidase­like 2a (Sppl2a). The chompB mutation re­
vealed an unexpected role for Sppl2a in B cell and DC devel­
opment and that Sppl2a­mediated processing of CD74 
contributes to the survival of those cells during development 
and activation.
RESULTS AND DISCUSSION
Identification of a role for Sppl2a in B cell  
and DC function by ENU mutagenesis
A mutant line with a heritable recessive mutation, named 
chompB, was identified with decreases in peripheral blood B cells 
and T cell–dependent antibody responses (Fig. 1, A and B). 
Single nucleotide polymorphism (SNP)–based mapping 
identified a region of chromosome 2 that was linked to these 
phenotypes (Fig. S1 A). Candidate gene sequencing identified 
a T to A conversion in the Sppl2a gene, resulting in a methio­
nine to lysine replacement (M252K) in the third transmem­
brane domain (unpublished data). Sppl2a has been shown to 
cleave TNF and promote inflammatory cytokine production 
by human DCs but its role in vivo has not been established 
(Fluhrer et al., 2006; Friedmann et al., 2006).
Analysis of B cells from the BM revealed a significant de­
crease in the number of mature recirculating B cells (Fig. 1 C). 
Analysis of splenic B cell populations revealed similar num­
bers of transitional 1 (T1) B cells but significant reductions in 
the numbers of T2, marginal zone (MZ), and follicular (FO) 
Figure 1. chompB mice have a block in  
B cell and DC development. (A and B) Muta-
genized mice were screened for blood B cells 
by B220 staining (A) and DNP-KLH–specific 
IgG by ELISA (B). (C) BM B cells were enumer-
ated by flow cytometry using the following 
criteria: pre/pro, B220+IgM; immature, 
B220+IgM+CD24+; mature/recirculating, 
B220+IgM+CD24. (D) Splenic B cell subsets 
were enumerated using the following criteria: 
T1, IgMhiCD21; T2, IgMhiCD21hiCD23+; FO, 
IgM+CD21lo; MZ, IgMhiCD21hiCD23. (E) B cell 
numbers in the lymph nodes were determined 
by gating on B220+ cells. (F) B1 cell numbers 
from the peritoneal cavity were enumerated 
using CD19+B220intCD5int. (G) DC numbers 
were determined using the following criteria: 
mDC, CD19CD3NK1.1CD11chi; pDC, CD19
CD3NK1.1CD11c+PDCA1+. (H and I) 50/50 
Mixed BM chimeras were analyzed by flow 
cytometry 8–12 wk after reconstitution. Data 
are expressed as the ratio of chompB to WT 
cells. Analysis of the B cells (H) and DCs  
(I) was performed using the gating schemes 
as in D and E after gating on CD45 variants to 
determine donor. *, P < 0.05; **, P < 0.01;  
***, P < 0.001 (mean, n = 3–5 in at least two 
independent experiments).
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mice had significant decreases in DNP­specific IgG1 after 
immunization; however, DNP­specific IgM levels were un­
affected (Fig. 2 B). The dramatic decrease in DNP­specific 
IgG1 cannot be explained solely by the threefold decrease in 
FO B cells, although it could be a contributing factor. Addi­
tionally, assessment of the ability of chompB B cells to respond 
to T cell help via class switching revealed a reduced ability to 
differentiate into IgG1+ cells (Fig. 2 G). The response to the 
T cell–independent antigen (TNP­Ficoll) was unchanged in 
chompB mutants, consistent with a lack of effect on the number 
of B1 B cells, which are known to contribute to this response 
(Fig. 2 C; Martin et al., 2001; Defrance et al., 2011).
We next assessed the ability of chompB mutant B cells to 
respond to stimuli in vitro. chompB B cells failed to proliferate 
in response to anti­IgM and exhibited reduced responses to 
LPS and anti­CD40 stimulation as indicated by dilution of CFSE 
(Fig. 2 D). Additional analyses revealed significantly decreased 
cell expansion as well as increased cell death in response 
to anti­IgM stimulation and, to a lesser extent, LPS (Fig. 2, 
E and F). Because FO B cells comprise 60% of B cells in the 
spleen of chompB mice as compared with 75% in control mice 
(unpublished results), the inability to proliferate in response 
to anti­IgM cannot be explained solely by alterations in B cell 
subsets, although this may be a contributing factor.
The chompB allele is a loss of function mutation in Sppl2a
We next investigated the nature of the defect in the chompB 
mutant Sppl2a. Epitope­tagged WT, chompB, and protease dead 
Sppl2a were expressed at similar levels (Fig. 3 A). Both WT and 
chompB versions of Sppl2a colocalized with the endosome 
marker Rab5, ruling out misfolding or altered localization 
(Fig. 3 C). WT and chompB mutant Sppl2a were also capable of 
cleaving the previously described substrate TNF to a similar 
extent (Fluhrer et al., 2006; Friedmann et al., 2006; Fig. 3, 
A and B). These results demonstrate the localization and function 
of the chompB mutant Sppl2a, at least when overexpressed, 
is largely comparable to WT. We speculate that the function 
and/or localization of the mutant Sppl2a at endogenous expres­
sion levels are altered. However, because of a lack of commer­
cially available anti­Sppl2a–specific antibodies, the endogenous 
expression of the chompB mutant was unable to be determined. 
Preliminary results confirmed that the mutation in Sppl2a was 
responsible for the phenotype of chompB mice, as transduction 
and transplant of chompB bone marrow with WT Sppl2a res­
cued the B cell developmental blockade (unpublished data).
To confirm that the phenotypes observed in the chompB 
mutants were a result of loss of function of Sppl2a, we obtained 
Figure 2. Defective T cell–dependent antibody responses and B 
cell activation in chompB mutants. (A) Ig levels were analyzed in 6–12-
wk-old WT and chompB mutant mice. (B) 6–12-wk-old WT and chompB 
mice were immunized with DNP-KLH and, after 14 d, DNP-specific anti-
body levels were determined by ELISA. (C) 6–12-wk-old WT and chompB 
mice were immunized with TNP-Ficoll and, after 14 d, TNP-specific anti-
body levels were determined by ELISA. (D–F) Purified B cells from WT and 
chompB mice were labeled with CFSE and cultured with the indicated 
stimuli along with 10 ng/ml rIL-4 for 72 h. CFSE dilution and cell death were 
then assessed by flow cytometry, and total cell numbers were determined 
by cell counting. (G) Expression of surface IgG1 in response to anti-CD40 
and IL-4 was assessed by flow cytometry after 96 h of culture (mean,  
n = 4–5 from two independent experiments, A–C; results are representative 
of at least three replicates from two independent experiments, D; mean 
and SEM of four independent experiments, E and F; and mean and SEM,  
n = 4 from two independent experiments, G). *, P < 0.05; **, P < 0.01;  
***, P < 0.001.
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The chompB mutation is a hypomorphic allele of Sppl2a
Despite the similarities, there were also differences between 
chompB mutant and Sppl2a/ mice. Unlike the chompB mice, 
the levels of DNP­specific IgM were decreased in Sppl2a/ 
mice after immunization (Fig. 3 F). Analysis of steady­state 
Ig levels also revealed decreases in all isotypes tested in the 
Sppl2a/ mice (Fig. 4 A). Additionally, the response to TNP­
Ficoll revealed a decrease in TNP­specific IgM and IgG3 in 
the Sppl2a/ mice (Fig. 4 B). Unlike the chompB mutants, 
there was a significant decrease in B1 B cells in the Sppl2a/ 
mice and this likely explains some of the observed differences 
between the two strains (Fig. 4 C). The similarities between 
the chompB and Sppl2a/ mice suggest that the chompB  
mutation in Sppl2a is a loss of function allele. However, the 
intact T cell–independent responses, B1 cell numbers, intact 
IgA and IgM levels, and assessment of activity when over­
expressed together suggest that the chompB mutation is a hypo­
morphic allele that maintains some level of activity in vivo.
Sppl2a/ mice. Analysis of Sppl2a/ mice revealed similar 
decreases in splenic B cells and mDCs compared with chompB 
mutants (Fig. 3, D and E). Also consistent with the chompB 
mice, DNP­specific IgG1 was decreased after immunization 
in Sppl2a/ mice (Fig. 3 F).
Figure 3. Mutation in Sppl2a is responsible for the observed 
defects in chompB mice. (A and B) HEK293T cells were cotransfected 
with the indicated plasmids, and TNF and Sppl2a levels were determined 
by Western blot. TNF-NTF (N-terminal fragment) was first normalized to 
full length TNF, followed by normalization to samples without Sppl2a 
for quantification (representative of four independent experiments for  
A and mean, n = 4 from four independent experiments for B). (C) U2OS 
cells were cotransfected with V5-mSppl2a together with Rab5-RFP. 
Cells were then stained with an anti-V5 antibody and Hoechst dye and 
analyzed by microscopy (representative of two independent experi-
ments). Bars, 20 µm. (D and E) Splenocytes from WT and Sppl2a/ mice 
were analyzed by flow cytometry as described in Fig. 1 (mean, n = 5 
from three independent experiments). (F) 6–12-wk-old WT and  
Sppl2a/ mice were immunized with DNP-KLH. DNP-specific anti-
body levels were determined by ELISA after 14 d (mean, n = 4–5 from 
two independent experiments). ***, P < 0.001. Figure 4. The chompB mutation in Sppl2a is a hypomorphic allele. 
(A) Plasma Ig levels were determined from WT and Sppl2a/ mice (mean, 
n = 4–5 from two independent experiments). (B) 6–12-wk-old WT and 
Sppl2a/ mice were immunized with TNP-Ficoll and TNP-specific anti-
body levels were determined by ELISA 14 d later (mean, n = 4–5, two in-
dependent experiments). (C) B1 cell numbers from the peritoneal cavity 
were defined as in Fig. 1 (mean, n = 5–7 from three independent experi-
ments). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Sppl2a-mediated cleavage of the N terminus of CD74  
is required for B cell survival
In addition to TNF, Sppl2a has been shown to cleave several 
substrates in vitro; however, none of these have been impli­
cated in B cell development (Kirkin et al., 2007; Martin et al., 
2008). To identify additional substrates, an unbiased pro­
teomics approach was used to compare the proteomes from 
WT and chompB B cells (Dix et al., 2008). This analysis identi­
fied accumulation of a fragment of CD74 in membrane­ 
enriched fractions from chompB but not WT B cells (Fig. 5 A). 
Although CD74 has been well studied for its role in MHC 
class II antigen presentation, it has also been implicated in 
B cell development (Kenty and Bikoff, 1999; Matza et al., 2002b; 
Stumptner­Cuvelette and Benaroch, 2002). Analysis of CD74 
by Western blot revealed accumulation of an 8­kD fragment 
(p8) in both Sppl2a/ and chompB cells consistent with the 
observations in the proteomics approach (Fig. 5 B). Cleavage 
of the p8 fragment by Sppl2a should generate a 4­kD frag­
ment (p4) but it is not detectible by Western blot. CD74 
processing was further analyzed in A20 mouse B cells using 
protease inhibitors (Fig. 5 C). Cathepsin inhibition (LHVS) 
led to accumulation of the CLIP­containing 10­kD fragment 
consistent with previous results (Riese et al., 1996). Treatment 
of B cells with Spp family active inhibitors (zLL2k and 
LY411,575) also led to accumulation of CD74 p8 (Nyborg 
et al., 2004). Because LY411,575 also has ­secretase activity, 
we tested a ­secretase selective inhibitor (LY450,139) which 
failed to block the processing of CD74 p8. These data are 
in contrast with a previous study demonstrating a role for 
­secretase, but not the Spp family, in CD74 processing 
(Becker­Herman et al., 2005). The reasons for the discrep­
ancies are unclear but could be a result of the differences in 
the systems used.
Deletion of CD74 prevents B cell and mDC loss  
in Sppl2a/ mice
The accumulation of CD74 p8 in the absence of Sppl2a could 
affect B cell and DC development/survival in several ways. 
Two possibilities are either that Sppl2a cleavage of p8 releases 
p4 which mediates cell signaling, or that accumulation of p8 
in the endosome is toxic. To differentiate between these pos­
sibilities, Sppl2a:CD74 double KO mice (DKO) were gener­
ated. If signaling via p4 were the predominant function of 
Sppl2a, DKO mice should have a similar phenotype as the 
Sppl2a/ mice. Alternatively, if the primary function of Sppl2a 
is to clear p8, the Sppl2a phenotype should be rescued in 
DKO mice. Analysis of B cell populations in the spleen re­
vealed a restoration of T2 and MZ B cells to WT levels in DKO 
mice (Fig. 5 D). Analysis of DCs also revealed a restoration in 
the mDC population to WT levels in DKO mice (Fig. 5 E). 
FO B cells were not restored in DKO mice, as CD74/ mice 
have decreased FO B cell numbers. Collectively, these data 
demonstrate that removal of CD74 p8 from endosomal mem­
branes is the primary function of Sppl2a and that CD74 is 
the key substrate of Sppl2a with respect to B cell and DC 
development/survival.
Figure 5. Sppl2a-mediated cleavage of CD74 is responsible for 
the B cell developmental blockade in chompB mice. (A) Pepto-
graph of CD74 from WT and chompB membrane-enriched fractions. 
The left side depicts the weight in kD and the right side depicts  
the frequency. (B) Western blot analysis of sorted mature B cells  
(CD24loCD21int) using antibodies to CD74 and -tubulin (representative 
of two independent experiments). (C) CD74 cleavage in A20 cells as-
sessed by Western blot (results are representative of at least three 
independent experiments). (D and E) B cell and DC numbers were 
determined using the same parameters in Fig. 1 (mean, n = 4 from 
three independent experiments). (F and G) Intracellular CD74 and 
MHC class II levels were determined using the gating schemes in Fig. 1 
for the indicated B cell (F) and DC (G) populations (n = 3, from two 
independent experiments). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
28 Sppl2a, CD74, and B cell development | Beisner et al.
flow cytometry. SNP mapping of the affected mice was performed as described 
elsewhere (Wiltshire et al., 2003). Sppl2a/ mice were purchased from Delta­
gen and backcrossed to C57BL/6 for five generations to >99% pure back­
ground using speed congenics. CD74/ mice (B6.129S6­Cd74tm1Liz/J; The 
Jackson Laboratory) have been described previously (Bikoff et al., 1993). All 
procedures were approved by the Genomics Institute of the Novartis Research 
Foundation Institutional Animal Care and Use Committee. Littermates were 
used as controls in the majority of experiments, but in some instances, C57BL/6 
mice from our internal colony were used as well.
Bone marrow transplant. Traditional mixed and single bone marrow 
chimeras were set up as previously described except the cells were transferred 
into the retro­orbital sinus region. (Miller et al., 2007).
Immunoglobulin levels. Immunoglobulin levels were measured from 
mouse plasma using an isotyping kit (Millipore) according to the manufac­
turer’s instructions.
Plasmids and cell transfection. Cell transfections in 293T cells were per­
formed using Lipofectamine 2000 (Invitrogen) according to the manufactur­
er’s instructions. In brief, 2 × 105 293T cells were cultured in 24­well plates 
(Costar), followed by additions of 1 µg of the indicated plasmids together 
with Lipofectamine in Opti­MEM (Invitrogen). 24 h after transfection, cells 
were released from the plate using 0.05% Trypsin (Invitrogen) and whole cell 
lysates, and Western blotting procedures were performed as described below. 
Plasmids for human Sppl2a (pCI­hSPPL2a) were described previously 
(Friedmann et al., 2006), and the chompB equivalent mutant (pCI­hSP­
PL2aM248K) and protease inactive mutant (pCI­hSPPL2aD412A) were 
generated by site­directed mutagenesis of the appropriate base pairs. Plasmids 
for mouse Sppl2a were generated by inserting the full length cDNA into the 
pCDNA3.1/V5­His­TOPO vector (Invitrogen) by PCR. The chompB ver­
sion was generated using site­directed mutagenesis of the appropriate base 
pairs. N­terminally tagged human TNF (pBICEP­CMV­2­TNF) was gener­
ated by introducing the full length cDNA into the pBICEP­CMV­2 vector 
(Sigma­Aldrich) using SalI and NotI sites. pCMV6­AC­RFP_Rab5 (express­
ing RFP­labeled endosome marker Rab5) was purchased from Origene.
Immunofluorescence. For immunofluorescence studies of transiently ex­
pressed proteins in U2OS cells, DNA (0.06 µg/well; 96­well plate) was diluted 
in Opti­MEM (Invitrogen) and incubated at room temperature for 5 min be­
fore addition of PEI (Polysciences) solution and 10­min incubation at room 
temperature. 104 cells/well were added to the preformed complexes and incu­
bated for 20 min at room temperature before the mixture was transferred into 
a clear­bottom 96­well plate. 24 h after transfection, cells were fixed with 4% 
paraformaldehyde for 15 min at room temperature, followed by 1 h of treat­
ment with blocking solution (4% BSA in PBS/0.1% Tween­20). Primary anti­
body directed against the V5 tag (Sigma­Aldrich) was added in PBS/0.1% 
Tween­20/1% BSA for 1 h and washed three times with PBS/0.1% Tween­20. 
The secondary antibody goat anti–mouse IgG Alexa Fluor 488 (Invitrogen) 
and Hoechst dye (1:10,000) were added in PBS/0.1% Tween­20/1% BSA for 
1 h, followed by three washes with PBS/0.1% Tween­20. Fluorescence 
images were taken with an Axio fluorescence microscope (Carl Zeiss).
Proteomics approach for substrate identification. Purified WT and 
chompB mutant B cells were resuspended in 50 mM Tris, pH 8.0, with appro­
priate amount of protease inhibitors (lysis solution) and probe was soni­
cated 3× 10 bursts on ice. Protein samples were centrifuged at 100,000 g for 
45 min as 4°C. The supernatant, the soluble proteome, was moved to a new 
tube and the pellet, the insoluble proteome, was washed three times with lysis 
solution and resuspended back into lysis solution by probe sonication. Proteins 
were quantified and 100 µg was mixed with protein loading dye for separa­
tion by SDS­PAGE. The rest of the procedure was performed as described 
previously (Dix et al., 2008).
B cell isolation and cell culture. Cell culture and isolation was per­
formed as described elsewhere (Beisner et al., 2003). Resting splenic B cells 
One open question relates to why post­T1 B cells and 
mDCs are particularly sensitive to loss of Sppl2a. One hy­
pothesis is that the sensitivity could be driven by increased 
expression of Sppl2a or CD74 in these cell types. Analysis of 
Sppl2a mRNA expression revealed similar levels in T1 and 
mature B cells (Fig. S1 C). In contrast, analysis of intracellular 
levels of CD74 and MHC class II on WT B cell subsets re­
vealed an increase between T1 and mature B cells, consis­
tent with timing of the B cell developmental blockade in 
Sppl2a/ mice (Fig. 5 F). Analysis of DCs also revealed ele­
vated levels of both proteins in mDCs compared with pDCs 
(Fig. 5 G). Collectively, these data suggest that Sppl2a is espe­
cially important in cells that contain high levels of MHC II 
and CD74 and that Sppl2a­mediated processing of CD74 p8 
is important for B cell and DC survival.
We have provided evidence that chompB mutant B cells 
have survival defects as a result of accumulation of CD74 p8. 
In contrast, previous work has suggested a role for CD74 in 
B cell development via p4 signaling (Matza et al., 2002a,b). 
However, the observation that mature B cell numbers are re­
stored in MHC class II:CD74 double­deficient mice suggests 
that the loss of FO B cells in CD74/ mice results from 
altered MHC class II trafficking rather than lack of p4 signal­
ing (Maehr et al., 2004). These data, together with the current 
work, provide strong support for the hypothesis that p8 accu­
mulation, rather than p4 loss, leads to B cell and mDC defects 
in Sppl2a/ mice. Two accompanying manuscripts in this 
issue by Schneppenheim et al. and Bergmann et al. support 
the general conclusions we have reached.
We speculate that Sppl2a permits higher levels of CD74 
and MHC class II expression and thereby facilitates effective 
sampling of the immune environment. Rapid turnover of 
MHC–peptide complexes ensures that antigen­presenting 
cells are able to present the most current range of foreign an­
tigens to ensure a rapid response to invading pathogens. How­
ever, a byproduct of this rapid turnover is high levels of 
membrane­bound p8 which are toxic to the cell. By degrading 
p8, Sppl2a prevents accumulation of this otherwise toxic 
byproduct of MHC Class II antigen processing and permits 
higher levels of MHC Class II and CD74 needed for efficient 
antigen sampling in specialized antigen­presenting cells.
The past decade of clinical experience with B cell deplet­
ing antibodies, such as Rituximab, has revealed a critical role for 
B cells in the pathogenesis of several autoimmune diseases. Our 
results raise the possibility that targeting Sppl2a may prove use­
ful for the treatment of autoimmune disease. However, given 
the essential role of Sppl2a in mediating B and DC develop­
ment, a thorough assessment of the therapeutic potential of 
Sppl2a will require the generation of appropriate inducible 
models that allow elimination of Sppl2a in mature cells.
MATERIALS AND METHODS
Mice. All mice used were 6–12 wk of age and were maintained in the specific 
pathogen­free facility of the Genomics Institute of the Novartis Research 
Foundation. C57BL/6 ENU­mutagenized mice were generated as described 
elsewhere (Miosge et al., 2002). B cell percentages in whole blood were 
measured using antibodies to B220 (eBioscience) and cells were analyzed by 
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